NYSE:ABT - Abbott Laboratories Stock Price, Forecast & News

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

Abbott Laboratories declared a quarterly dividend on Friday, December 13th. Stockholders of record on Wednesday, January 15th will be paid a dividend of $0.36 per share on Friday, February 14th. This represents a $1.44 dividend on an annualized basis and a dividend yield of 1.61%. The ex-dividend date of this dividend is Tuesday, January 14th. This is a boost from Abbott Laboratories's previous quarterly dividend of $0.32. View Abbott Laboratories' Dividend History.

Abbott Laboratories (NYSE:ABT) posted its quarterly earnings results on Wednesday, January, 22nd. The healthcare product maker reported $0.95 earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of $0.95. The healthcare product maker had revenue of $8.31 billion for the quarter, compared to analyst estimates of $8.26 billion. Abbott Laboratories had a return on equity of 18.34% and a net margin of 11.56%. The business's quarterly revenue was up 7.1% compared to the same quarter last year. During the same period last year, the business posted $0.81 earnings per share. View Abbott Laboratories' Earnings History.

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, April 15th 2020. View Earnings Estimates for Abbott Laboratories.

Abbott Laboratories issued an update on its FY20 earnings guidance on Wednesday, January, 22nd. The company provided EPS guidance of $3.55-3.65 for the period, compared to the Thomson Reuters consensus estimate of $3.60.

16 equities research analysts have issued 12-month price objectives for Abbott Laboratories' shares. Their forecasts range from $81.00 to $105.00. On average, they expect Abbott Laboratories' share price to reach $95.77 in the next twelve months. This suggests a possible upside of 6.9% from the stock's current price. View Analyst Price Targets for Abbott Laboratories.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 2 sell ratings, 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Abbott Laboratories.

News coverage about ABT stock has been trending somewhat negative recently, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Abbott Laboratories earned a coverage optimism score of -1.4 on InfoTrie's scale. They also gave news articles about the healthcare product maker a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Abbott Laboratories.

Some companies that are related to Abbott Laboratories include Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR), Steris (STE) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Abbott Laboratories investors own include AbbVie (ABBV), AT&T (T), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Walt Disney (DIS), NVIDIA (NVDA), Home Depot (HD), Pfizer (PFE), Intel (INTC) and Micron Technology (MU).

Abbott Laboratories' stock is owned by a variety of of institutional and retail investors. Top institutional investors include California Public Employees Retirement System (0.23%), New York State Teachers Retirement System (0.15%), Loring Wolcott & Coolidge Fiduciary Advisors LLP MA (0.11%), Strs Ohio (0.09%), Everett Harris & Co. CA (0.09%) and Gateway Investment Advisers LLC (0.05%). Company insiders that own Abbott Laboratories stock include Andrew H Lane, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Daniel J Starks, Hubert L Allen, Jaime Contreras, Jared Watkin, John G Stratton, John M Capek, Joseph J Manning, Michael J Pederson, Miles D White, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.

ABT stock was sold by a variety of institutional investors in the last quarter, including Columbus Circle Investors, Calamos Advisors LLC, Norris Perne & French LLP MI, OLD National Bancorp IN, Artemis Investment Management LLP, Meag Munich Ergo Kapitalanlagegesellschaft MBH, Virginia Retirement Systems ET AL and Strs Ohio. Company insiders that have sold Abbott Laboratories company stock in the last year include Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, John M Capek, Joseph J Manning, Michael J Pederson, Miles D White, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.

ABT stock was bought by a variety of institutional investors in the last quarter, including Milestone Resources Group Ltd, Johanson Financial Advisors Inc., California Public Employees Retirement System, Garnet Equity Capital Holdings Inc., Executive Wealth Management LLC, Janney Montgomery Scott LLC, Rockland Trust Co. and United Services Automobile Association. Company insiders that have bought Abbott Laboratories stock in the last two years include Daniel J Starks, John G Stratton and Randel William Woodgrift. View Insider Buying and Selling for Abbott Laboratories.

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ABT stock can currently be purchased for approximately $89.59.

Abbott Laboratories has a market capitalization of $158.44 billion and generates $31.90 billion in revenue each year. The healthcare product maker earns $3.69 billion in net income (profit) each year or $3.24 on an earnings per share basis. Abbott Laboratories employs 103,000 workers across the globe.View Additional Information About Abbott Laboratories.

The official website for Abbott Laboratories is http://www.abbott.com/.

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.